18th May 2016 07:24
LONDON (Alliance News) - Respiratory drug development company Skyepharma PLC on Wednesday said trading in the first four months of 2016 was good, and it continues to anticipate strong growth in revenue for the full year.
Skyepharma said its Flutiform asthma treatment has continued to benefit from growing demand and has now been launched in 31 countries, approved in another seven, and has applications for marketing authorisations under review in 16 more.
Good progress has also been made on broadening the approved indication for the treatment, with filings for chronic obstructive pulmonary disease indications anticipated soon in Europe and China.
Skyepharma also noted the UK Competition & Markets Authority this week said its proposed merger with FTSE 250-listed respiratory drugs peer Vectura Group PLC did not qualify for investigation on competition grounds, leaving the deal free to complete in due course.
Skyepharma shares were up 0.1% to 472.00 pence early Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.